Evan S Dellon1, John T Woosley2, Ashley Arrington3, Sarah J McGee3, Jacquelyn Covington3, Susan E Moist3, Jessica H Gebhart3, Joseph A Galanko3, John A Baron3, Nicholas J Shaheen3. 1. Center for Esophageal Diseases and Swallowing, Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, Chapel Hill, North Carolina. Electronic address: edellon@med.unc.edu. 2. Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina. 3. Center for Esophageal Diseases and Swallowing, Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, Chapel Hill, North Carolina.
Abstract
BACKGROUND & AIMS: Eosinophilic esophagitis (EoE) is chronic and recurs if treatment is discontinued. We aimed to determine rates of recurrence, and whether initial treatment with oral viscous budesonide (OVB) resulted in less recurrence than fluticasone from a multidose inhaler (MDI). METHODS: This was the observation phase of a randomized, double-blind, double-dummy trial comparing OVB with MDI for initial EoE treatment. Subjects with a histologic response (<15 eosinophils/high-power field) in the trial entered an observation phase in which treatment was discontinued and symptoms were monitored. Patients underwent an endoscopy or a biopsy when symptoms recurred or at 1 year. We analyzed time to symptom recurrence and assessed endoscopic severity and histologic relapse (≥15 eosinophils/high-power field) at follow-up endoscopy. RESULTS: Thirty-three of the 58 subjects (57%) had symptom recurrence before 1 year. The overall median time to symptom recurrence was 244 days. There was no difference in the rate of symptom recurrence for subjects treated with OVB vs MDI (hazard ratio, 1.04; 95% CI, 0.52-2.08). At symptom recurrence, 78% of patients had histologic relapse. The patients had significant increases in mean Dysphagia Symptom Questionnaire score (3.8 vs 8.7; P < .001), and the EoE Endoscopic Reference Score (1.3 vs 4.6; P < .001) compared with end of treatment. CONCLUSIONS: EoE disease activity recurred rapidly after initial histologic response to topical steroids (either OVB or MDI). Because most subjects had recurrent endoscopic and histologic signs not reliably detected by symptoms, maintenance therapy should be recommended in EoE patients achieving histologic response to topical steroids. Clinicaltrials.gov no: NCT02019758.
RCT Entities:
BACKGROUND & AIMS:Eosinophilic esophagitis (EoE) is chronic and recurs if treatment is discontinued. We aimed to determine rates of recurrence, and whether initial treatment with oral viscous budesonide (OVB) resulted in less recurrence than fluticasone from a multidose inhaler (MDI). METHODS: This was the observation phase of a randomized, double-blind, double-dummy trial comparing OVB with MDI for initial EoE treatment. Subjects with a histologic response (<15 eosinophils/high-power field) in the trial entered an observation phase in which treatment was discontinued and symptoms were monitored. Patients underwent an endoscopy or a biopsy when symptoms recurred or at 1 year. We analyzed time to symptom recurrence and assessed endoscopic severity and histologic relapse (≥15 eosinophils/high-power field) at follow-up endoscopy. RESULTS: Thirty-three of the 58 subjects (57%) had symptom recurrence before 1 year. The overall median time to symptom recurrence was 244 days. There was no difference in the rate of symptom recurrence for subjects treated with OVB vs MDI (hazard ratio, 1.04; 95% CI, 0.52-2.08). At symptom recurrence, 78% of patients had histologic relapse. The patients had significant increases in mean Dysphagia Symptom Questionnaire score (3.8 vs 8.7; P < .001), and the EoE Endoscopic Reference Score (1.3 vs 4.6; P < .001) compared with end of treatment. CONCLUSIONS: EoE disease activity recurred rapidly after initial histologic response to topical steroids (either OVB or MDI). Because most subjects had recurrent endoscopic and histologic signs not reliably detected by symptoms, maintenance therapy should be recommended in EoE patients achieving histologic response to topical steroids. Clinicaltrials.gov no: NCT02019758.
Authors: Marijn J Warners; Renske A B Oude Nijhuis; Laetitia R H de Wijkerslooth; Andreas J P M Smout; Albert J Bredenoord Journal: Am J Gastroenterol Date: 2018-04-27 Impact factor: 10.864
Authors: Evan S Dellon; John T Woosley; Ashley Arrington; Sarah J McGee; Jacquelyn Covington; Susan E Moist; Jessica H Gebhart; Alexandra E Tylicki; Shiyan O Shoyoye; Christopher F Martin; Joseph A Galanko; John A Baron; Nicholas J Shaheen Journal: Gastroenterology Date: 2019-03-11 Impact factor: 22.682
Authors: Evan S Dellon; Karen J Fritchie; Tara C Rubinas; John T Woosley; Nicholas J Shaheen Journal: Dig Dis Sci Date: 2009-10-15 Impact factor: 3.199
Authors: Craig C Reed; W Asher Wolf; Cary C Cotton; Spencer Rusin; Irina Perjar; Johnathan Hollyfield; John T Woosley; Nicholas J Shaheen; Evan S Dellon Journal: Clin Gastroenterol Hepatol Date: 2017-10-04 Impact factor: 11.382
Authors: Joy W Chang; Vincent L Chen; Joel H Rubenstein; Evan S Dellon; Lauren P Wallner; Raymond De Vries Journal: Dis Esophagus Date: 2022-06-15 Impact factor: 2.822
Authors: Christopher Ma; Alain M Schoepfer; Evan S Dellon; Albert J Bredenoord; Mirna Chehade; Margaret H Collins; Brian G Feagan; Glenn T Furuta; Sandeep K Gupta; Ikuo Hirano; Vipul Jairath; David A Katzka; Rish K Pai; Marc E Rothenberg; Alex Straumann; Seema S Aceves; Jeffrey A Alexander; Nicoleta C Arva; Dan Atkins; Luc Biedermann; Carine Blanchard; Antonella Cianferoni; Constanza Ciriza de Los Rios; Frederic Clayton; Carla M Davis; Nicola de Bortoli; Jorge A Dias; Gary W Falk; Robert M Genta; Gisoo Ghaffari; Nirmala Gonsalves; Thomas Greuter; Russell Hopp; Karen S Hsu Blatman; Elizabeth T Jensen; Doug Johnston; Amir F Kagalwalla; Helen M Larsson; John Leung; Hubert Louis; Joanne C Masterson; Calies Menard-Katcher; Paul A Menard-Katcher; Fouad J Moawad; Amanda B Muir; Vincent A Mukkada; Roberto Penagini; Robert D Pesek; Kathryn Peterson; Philip E Putnam; Alberto Ravelli; Edoardo V Savarino; Christoph Schlag; Philipp Schreiner; Dagmar Simon; Thomas C Smyrk; Jonathan M Spergel; Tiffany H Taft; Ingrid Terreehorst; Tim Vanuytsel; Carina Venter; Mario C Vieira; Michael Vieth; Berber Vlieg-Boerstra; Ulrike von Arnim; Marjorie M Walker; Joshua B Wechsler; Philip Woodland; John T Woosley; Guang-Yu Yang; Noam Zevit; Ekaterina Safroneeva Journal: J Allergy Clin Immunol Date: 2021-07-06 Impact factor: 10.793
Authors: Thomas Greuter; Anne Godat; Amit Ringel; Hector Samuel Almonte; Daniel Schupack; Gabriela Mendoza; Talaya McCright-Gill; Evan S Dellon; Ikuo Hirano; Jeffrey Alexander; Mirna Chehade; Ekaterina Safroneeva; Christian Bussmann; Luc Biedermann; Philipp Schreiner; Alain M Schoepfer; Alex Straumann; David A Katzka Journal: Clin Gastroenterol Hepatol Date: 2020-08-13 Impact factor: 11.382